Treatment of cancer-associated venous thromboembolism: A focus on special populations.
Brain cancer
Cancer-associated thrombosis
Drug–drug interactions
Gastrointestinal cancer
Renal impairment
Thrombocytopenia
Journal
Journal de medecine vasculaire
ISSN: 2542-4513
Titre abrégé: J Med Vasc
Pays: France
ID NLM: 101709200
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
20
07
2023
accepted:
02
09
2023
medline:
3
11
2023
pubmed:
2
11
2023
entrez:
1
11
2023
Statut:
ppublish
Résumé
Current evidence-based clinical practice guidelines recommend the use of both low-molecular-weight heparin (LMWH) and direct factor Xa inhibitors (apixapan, edoxaban and rivaroxaban) as first-line options for the treatment of venous thromboembolism (VTE) in patients with cancer. However, most of these guidelines refer to the general cancer patient population and provide limited guidance for specific subgroups of patients at particularly high risk of bleeding, such as those with gastrointestinal cancers, primary or metastatic brain tumors, thrombocytopenia, or renal impairment. In these complex populations, the management of cancer-associated thrombosis (CAT) poses unique challenges and requires a nuanced approach based on the primum non nocere principle. This comprehensive review critically examines the relevant literature and discusses the therapeutic options currently available for the management of CAT in these special situations.
Identifiants
pubmed: 37914457
pii: S2542-4513(23)00083-4
doi: 10.1016/j.jdmv.2023.09.001
pii:
doi:
Substances chimiques
Heparin, Low-Molecular-Weight
0
Rivaroxaban
9NDF7JZ4M3
Factor Xa Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
124-135Informations de copyright
Copyright © 2023 Elsevier Masson SAS. All rights reserved.